Though a Phase III trial of Biocon
Ltd.'s anti-CD6 mAb itolizumab did not show as much efficacy as other
biologics in psoriasis, the biotech thinks lower infection rates could
differentiate the mAb from the anti-TNFs.
Biocon this month announced
itolizumab met the primary endpoint of PASI 75 improvement compared to placebo
after 12 weeks (36% vs. 2%, p<0.0043) in the Indian Phase III TREAT-PLAQ
trial in 223 patients with moderate to severe psoriasis.